Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$236.72
$254.83
$186.05
▼
$282.15
$14.77B0.35730,003 shs1.56 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$34.74
$31.50
$23.62
▼
$35.43
$21.67B0.841.89 million shs2.71 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$494.63
$515.48
$408.75
▼
$609.35
$21.21B0.56667,789 shs1.48 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$39.75
$62.12
$35.97
▼
$72.66
$3.84B0.611.51 million shs17.88 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%-10.17%-6.54%+3.82%+19.75%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+6.99%+3.86%+35.65%+22.84%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
0.00%-0.50%-3.60%-8.11%+18.45%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
0.00%-32.23%-34.59%-27.45%+7.58%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$236.72
$254.83
$186.05
▼
$282.15
$14.77B0.35730,003 shs1.56 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$34.74
$31.50
$23.62
▼
$35.43
$21.67B0.841.89 million shs2.71 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$494.63
$515.48
$408.75
▼
$609.35
$21.21B0.56667,789 shs1.48 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$39.75
$62.12
$35.97
▼
$72.66
$3.84B0.611.51 million shs17.88 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%-10.17%-6.54%+3.82%+19.75%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+6.99%+3.86%+35.65%+22.84%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
0.00%-0.50%-3.60%-8.11%+18.45%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
0.00%-32.23%-34.59%-27.45%+7.58%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$310.7531.27% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.85
Moderate Buy$39.5013.70% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.85
Moderate Buy$646.0030.60% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.94
Moderate Buy$70.9378.45% Upside

Current Analyst Ratings Breakdown

Latest XENE, UTHR, GMAB, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$69.00 ➝ $64.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$90.00 ➝ $46.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy ➝ Hold$46.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$81.00 ➝ $70.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$71.00 ➝ $55.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$97.00 ➝ $90.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$78.00 ➝ $60.00
9/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$344.00
9/15/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$287.00
9/14/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00
(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M18.13N/AN/A($2.97) per share-79.70
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.72B5.83$1.61 per share21.58$9.10 per share3.82
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.18B6.67$33.00 per share14.99$164.81 per share3.00
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M512.35N/AN/A$7.53 per share5.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8918.3626.69N/A70.99%32.54%7.71%11/11/2026 (Estimated)
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.2727.3522.131.8919.08%14.89%7.73%11/5/2026 (Estimated)
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$27.9517.7016.682.4841.56%20.18%17.98%11/4/2026 (Estimated)
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$345.91M-$4.74N/AN/AN/AN/A-43.98%-41.72%11/2/2026 (Estimated)

Latest XENE, UTHR, GMAB, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/6/2026Q2 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.37$0.54+$0.17$0.4910$1.12 billion$1.16 billion
8/6/2026Q2 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.16-$1.11+$0.05-$1.11$1.67 millionN/A
8/5/2026Q2 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.86$7.27+$0.41$7.27$804.65 million$783.30 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.81
2.46
2.44
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
5.73
5.41
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
21.01
21.02

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
8.60%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029623.78 million614.17 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.89 million39.20 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
37096.67 million93.85 millionOptionable

Recent News About These Companies

Xenon Pharmaceuticals Inc (XENE)
September 20 at 2:39 PM  |  za.investing.comhttps://za.investing.com/equities/xenon-pharmaceuticals-consensus-estimates
Robert W. Baird Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price
September 20 at 3:22 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31034223
Needham & Company LLC Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price
September 20 at 3:22 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31034216
Royal Bank Of Canada Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $70.00
September 20 at 2:40 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31033910
Wedbush Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00
September 20 at 2:02 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31033817
Goldman Sachs Sticks to Its Buy Rating for Xenon (XENE)
September 19 at 11:21 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XENE-Q/pressreleases/4694474/goldman-sachs-sticks-to-its-buy-rating-for-xenon-xene/
Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data
September 19 at 11:21 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/why-xenon-pharmaceuticals-xene-down-002009302.html
Xenon Pharmaceuticals (NASDAQ:XENE) Downgraded to "Strong Sell" Rating by Wall Street Zen
September 19 at 1:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-xenon-pharmaceuticals-nasdaq-xene-downgraded-to-strong-sell-rating-by-wall-street-zen-2026-09-19/
Xenon: The Psychiatry Pause Matters More Than You Think (Rating Downgrade)
September 18 at 10:14 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4947905-xenon-the-psychiatry-pause-matters-than-you-think-rating-downgrade
XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial
September 18 at 10:14 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/xene-stock-plummets-xenon-pharmaceuticals-190004522.html
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause
September 18 at 12:24 PM  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1098767?snapi
Xenon Pharma Tumbles On Azetukalner Psychiatry Trial Enrollment Pause; Files Focal Seizure NDA
September 18 at 12:12 PM  |  rttnews.comhttps://www.rttnews.com/3692106/xenon-pharma-tumbles-on-azetukalner-psychiatry-trial-enrollment-pause-files-focal-seizure-nda.aspx
Is Xenon Pharmaceuticals (XENE) Stock a Buy After Its Worst Drop in Nearly a Decade?
September 18 at 12:12 PM  |  coincentral.comC
The Biotech Surged 50% On Positive Data In March. Now, It's Almost Gone.
September 18 at 12:12 PM  |  investors.comhttps://www.investors.com/news/technology/xenon-pharmaceuticals-azetukalner-side-effects-biotech-stock/
Xenon Pharmaceuticals (XENE) Plunges 25% on Psychiatric Trial Halt: Is Now the Time to Buy?
September 18 at 12:12 PM  |  blockonomi.comhttps://blockonomi.com/xenon-pharmaceuticals-xene-plunges-25-on-psychiatric-trial-halt-is-now-the-time-to-buy/
Xenon Pharmaceuticals' Azetukalner Retains Core Epilepsy Value, RBC Capital Markets Says
September 18 at 12:12 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/xenon-pharmaceuticals-apos-azetukalner-retains-152123214.html
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
September 18 at 12:12 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/xene-files-nda-epilepsy-drug-150900924.html
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
September 18 at 12:10 PM  |  zacks.comhttps://www.zacks.com/stock/news/2992238/xene-files-nda-for-epilepsy-drug-falls-on-depression-studies-setback?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2992238
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down on Analyst Downgrade
September 18 at 10:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xenon-pharmaceuticals-nasdaq-xene-shares-gap-down-on-analyst-downgrade-2026-09-18/
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $70.00 by Analysts at Royal Bank Of Canada
September 18 at 10:17 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-xenon-pharmaceuticals-nasdaq-xene-price-target-cut-to-7000-by-analysts-at-royal-bank-of-canada-2026-09-18/
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $55.00 by Analysts at Wedbush
September 18 at 9:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-xenon-pharmaceuticals-nasdaq-xene-price-target-cut-to-5500-by-analysts-at-wedbush-2026-09-18/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$236.72 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$238.46 +1.74 (+0.74%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$34.74 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$34.34 -0.40 (-1.15%)
As of 04:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$494.63 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$494.73 +0.10 (+0.02%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$39.75 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$40.12 +0.37 (+0.92%)
As of 04:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas